After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Portuguese state-owned bank Caixa Geral de Depositos SA is analyzing the possible acquisition of Novo Banco SA, a smaller ...

Ex Novo Brewing Company, founded in 2014 by Corrales Native Joel Gregory, began its journey in Portland, Oregon, with a ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Novo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...

Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

Gensaic partnership with Novo Nordisk, worth up to $354M, aims to develop next-generation precision therapies using novel protein design technology.

Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...